Patents Assigned to Chroma Therapeutics Limited
  • Adenine derivative as inhibitors of HSP90 for the treatment of cancer
    Patent number: 8217050
    Abstract: The invention provides a compound which is (a) an amino acid derivative of formula (I) or a tautomer thereof, or (b) a pharmaceutically acceptable salt, N-oxide, hydrate or solvate thereof: wherein R1, R2, L1, Het, A, x, y and W are as defined herein. The compounds are useful in the treatment of diseases mediated by HSP90.
    Type: Grant
    Filed: November 5, 2007
    Date of Patent: July 10, 2012
    Assignee: Chroma Therapeutics Limited
    Inventors: David Festus Charles Moffat, Simon Christopher Hirst, Stuart Thomas Onions
  • Carboline and betacarboline derivatives for use as hdac enzyme inhibitors
    Publication number: 20060235012
    Abstract: Compounds of formula (IA) and (IB) are inhibitors of histone deacetylase activity and useful for the treatment of, inter alia, cancers: wherein fused rings A1 and A2 are optionally substituted; linker radical R1 represents a radical of formula
    Type: Application
    Filed: June 15, 2004
    Publication date: October 19, 2006
    Applicant: Chroma Therapeutics Limited
    Inventors: Alan Davidson, Christopher Yarnold, Charlton Hugh
  • Assays, methods and means for modulating e2f activity
    Patent number: 6890709
    Abstract: P/CAF interacts with and acetylates E2F, this acetylation affecting ability of E2F to stimulate transcription. Interaction between P/CAF and E2F and acetylation of E2F by P/CAF are modulated, affecting ability of E2F to stimulate transcription, induction of S-phase in cells, oncogenicity of cells, and induction of apoptosis in cells. Agents are obtained for treatment of disorders of cell growth.
    Type: Grant
    Filed: May 17, 1999
    Date of Patent: May 10, 2005
    Assignee: Chroma Therapeutics Limited
    Inventor: Tony Kouzarides
  • Assays, methods and means for modulating nuclear localization
    Patent number: 6747005
    Abstract: CBP histone acetyltransferase acetylates Importin &agr;, affecting ability of Importin &agr; to translate into the nucleus and import a cargo protein. Assays identify substances which modulate interaction between CBP and Importin &agr; and acetylation of Importin &agr; by CBP. Substances identified in the assays are useful for treatment of disorders in which Imporin &agr; plays a role.
    Type: Grant
    Filed: January 25, 2001
    Date of Patent: June 8, 2004
    Assignee: Chroma Therapeutics Limited
    Inventor: Tony Kouzarides